Terms: = Ovarian cancer AND CXCR4, D2S201E, 7852, ENSG00000121966, P61073, NPYY3R, NPY3R, HM89, NPYRL, LESTR, HSY3RR, LCR1, fusin, WHIM, NPYR, FB22, CD184
125 results:
1. CRISPR du-HITI an attractive approach to targeting Long Noncoding RNA HCP5 as inhibitory factor for proliferation of ovarian cancer cell.
Moradi Z; Kazemi M; Jamshidi-Khalifelou R; Bahramnia V; Esfandmaz F; Rahnavard R; Moradgholi B; Piri-Gharaghie T
Funct Integr Genomics; 2024 Mar; 24(2):61. PubMed ID: 38507114
[TBL] [Abstract] [Full Text] [Related]
2. Single-cell analysis reveals the stromal dynamics and tumor-specific characteristics in the microenvironment of ovarian cancer.
Zhang L; Cascio S; Mellors JW; Buckanovich RJ; Osmanbeyoglu HU
Commun Biol; 2024 Jan; 7(1):20. PubMed ID: 38182756
[TBL] [Abstract] [Full Text] [Related]
3. cxcr4-directed PET/CT with [
Dreher N; Hahner S; Fuß CT; Schlötelburg W; Hartrampf PE; Serfling SE; Schirbel A; Samnick S; Higuchi T; Weich A; Lapa C; Rosenwald A; Buck AK; Kircher S; Werner RA
Eur J Nucl Med Mol Imaging; 2024 Apr; 51(5):1383-1394. PubMed ID: 38082196
[TBL] [Abstract] [Full Text] [Related]
4. MUC16 stimulates neutrophils to an inflammatory and immunosuppressive phenotype in ovarian cancer.
Wu Y; Liu Q; Xie Y; Zhu J; Zhang S; Ge Y; Guo J; Luo N; Huang W; Xu R; Liu S; Cheng Z
J Ovarian Res; 2023 Aug; 16(1):181. PubMed ID: 37644468
[TBL] [Abstract] [Full Text] [Related]
5. ROLE OF STROMAL MICROENVIRONMENT IN THE FORMATION OF INVASIVE, ANGIOGENIC, AND METASTATIC POTENTIAL OF ENDOMETRIOID CARCINOMA OF ENDOMETRIUM.
Iurchenko NP; Nesina IP; Glushchenko NМ; Buchynska LG
Exp Oncol; 2023 Jun; 45(1):51-61. PubMed ID: 37417282
[TBL] [Abstract] [Full Text] [Related]
6. Tissue Expression and Prognostic Role of CXCL12 and cxcr4 in High-grade Serous ovarian Carcinoma.
Lim H; Kim SI; Kim EN; Lee M; Lee C; Kim JW; Chung HH
Anticancer Res; 2023 Jul; 43(7):3331-3340. PubMed ID: 37351997
[TBL] [Abstract] [Full Text] [Related]
7. cancer-associated fibroblasts contribute to cancer metastasis and apoptosis resistance in human ovarian cancer via paracrine SDF-1α.
Dai JM; Sun K; Li C; Cheng M; Guan JH; Yang LN; Zhang LW
Clin Transl Oncol; 2023 Jun; 25(6):1606-1616. PubMed ID: 36593384
[TBL] [Abstract] [Full Text] [Related]
8. The role of selected molecular factors in ovarian cancer metastasis.
Markowska A; Sawicki W; Zurawski J; Fechner J; Markowska J
Ginekol Pol; 2022; 93(8):670-674. PubMed ID: 35894484
[TBL] [Abstract] [Full Text] [Related]
9. cxcr4 knockdown enhances sensitivity of paclitaxel via the PI3K/Akt/mTOR pathway in ovarian carcinoma.
Zi D; Li Q; Xu CX; Zhou ZW; Song GB; Hu CB; Wen F; Yang HL; Nie L; Zhao X; Tan J; Zhou SF; He ZX
Aging (Albany NY); 2022 Jun; 14(11):4673-4698. PubMed ID: 35681259
[TBL] [Abstract] [Full Text] [Related]
10. Effect of bevacizumab combined with chemotherapy on SDF-1 and cxcr4 in epithelial ovarian cancer and its prognosis.
Ma C
World J Surg Oncol; 2022 May; 20(1):154. PubMed ID: 35545781
[TBL] [Abstract] [Full Text] [Related]
11. High ratio of pcxcr4/cxcr4 tumor infiltrating immune cells in primary high grade ovarian cancer is indicative for response to chemotherapy.
Walther F; Berther JL; Lalos A; Ramser M; Eichelberger S; Mechera R; Soysal S; Muenst S; Posabella A; Güth U; Stadlmann S; Terracciano L; Droeser RA; Zeindler J; Singer G
BMC Cancer; 2022 Apr; 22(1):376. PubMed ID: 35397601
[TBL] [Abstract] [Full Text] [Related]
12. Non-invasive detection and complementary diagnosis of liver metastases via chemokine receptor 4 imaging.
Yang H; Tan S; Qiao J; Xu Y; Gui Z; Meng Y; Dong B; Peng G; Ibhagui OY; Qian W; Lu J; Li Z; Wang G; Lai J; Yang L; Grossniklaus HE; Yang JJ
Cancer Gene Ther; 2022 Dec; 29(12):1827-1839. PubMed ID: 35145271
[TBL] [Abstract] [Full Text] [Related]
13. cxcr4 and RIF1 overexpression induces resistance of epithelial ovarian cancer to cisplatin-based chemotherapy.
Sad LMAE; Mohamed DA; Elanwar NM; Elkady A
J Cancer Res Ther; 2021; 17(6):1454-1461. PubMed ID: 34916377
[TBL] [Abstract] [Full Text] [Related]
14. MicroRNA-33b replacement effect on growth and migration inhibition in ovarian cancer cells.
Liu J; Wang W; Chen L; Li Y; Zhao S; Liang Y
Chem Biol Drug Des; 2023 May; 101(5):1019-1026. PubMed ID: 34590776
[TBL] [Abstract] [Full Text] [Related]
15. Expression of chemokine receptor cxcr4 in tumor cells and content of CXCL12
Buchynska LG; Movchan OM; Iurchenko NP
Exp Oncol; 2021 Jun; 43(2):135-141. PubMed ID: 34190517
[TBL] [Abstract] [Full Text] [Related]
16. Single-cell dissection of cellular components and interactions shaping the tumor immune phenotypes in ovarian cancer.
Hornburg M; Desbois M; Lu S; Guan Y; Lo AA; Kaufman S; Elrod A; Lotstein A; DesRochers TM; Munoz-Rodriguez JL; Wang X; Giltnane J; Mayba O; Turley SJ; Bourgon R; Daemen A; Wang Y
Cancer Cell; 2021 Jul; 39(7):928-944.e6. PubMed ID: 33961783
[TBL] [Abstract] [Full Text] [Related]
17. Determination of Potential Therapeutic Targets and Prognostic Markers of ovarian cancer by Bioinformatics Analysis.
Zhang J; Huang S; Quan L; Meng Q; Wang H; Wang J; Chen J
Biomed Res Int; 2021; 2021():8883800. PubMed ID: 33829065
[TBL] [Abstract] [Full Text] [Related]
18. Recent Advances in Tannic Acid (Gallotannin) Anticancer Activities and Drug Delivery Systems for Efficacy Improvement; A Comprehensive Review.
A Youness R; Kamel R; A Elkasabgy N; Shao P; A Farag M
Molecules; 2021 Mar; 26(5):. PubMed ID: 33803294
[TBL] [Abstract] [Full Text] [Related]
19. Construction autophagy-related prognostic risk signature to facilitate survival prediction, individual treatment and biomarker excavation of epithelial ovarian cancer patients.
Fei H; Chen S; Xu C
J Ovarian Res; 2021 Mar; 14(1):41. PubMed ID: 33676525
[TBL] [Abstract] [Full Text] [Related]
20. The efficacy of PD-1/PD-L1 blockade in cold cancers and future perspectives.
Majidpoor J; Mortezaee K
Clin Immunol; 2021 May; 226():108707. PubMed ID: 33662590
[TBL] [Abstract] [Full Text] [Related]
[Next]
